Yan Q, Liu J. Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies. haematol [Internet]. 2025May1 [cited 2025Dec.5];110(5):1236. Available from: https://haematologica.org/article/view/11925